Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma

Br J Cancer. 1976 Aug;34(2):174-9. doi: 10.1038/bjc.1976.140.


Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C+I) received the same chemotherapy but were also immunized with 2 X 10(7) irradiated allogeneic melanoma cells mixed with 50 mug of percutaneous BCG. The survival rates in both treatment groups C and (C+I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C+I) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Antigens, Neoplasm
  • BCG Vaccine / therapeutic use
  • Dacarbazine / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunotherapy*
  • Male
  • Melanoma / drug therapy
  • Melanoma / immunology
  • Melanoma / therapy*
  • Piperazines / therapeutic use*
  • Prognosis
  • Razoxane / therapeutic use*
  • Triazenes / therapeutic use*


  • Antigens, Neoplasm
  • BCG Vaccine
  • Piperazines
  • Triazenes
  • Razoxane
  • Dacarbazine